Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 29; no. 15_suppl; p. e14002
Main Authors Ychou, M., Bouche, O., Thézenas, S., Francois, E., Adenis, A., Bennouna, J., Taïeb, J., Desseigne, F., Seitz, J., Conroy, T., Galais, M., Crapez, E., Poujol, S., Bibeau, F., Laurent-Puig, P., Samalin, E.
Format Journal Article
LanguageEnglish
Published 20.05.2011
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2011.29.15_suppl.e14002